Project description
Artificial intelligence for dementia prevention
Every three seconds someone in the world develops dementia. There are over 50 million people worldwide living with dementia and by 2030 this figure is expected to reach 82 million. Besides time-consuming patient investigations with low discriminative power for dementia risk, current treatment options focus on late symptom management. By screening brain connectivity and dementia risk estimation in people affected by mild cognitive impairment, the EU-funded AI-Mind project will open the door to extending the ‘dementia-free’ period by offering proper diagnosis and early intervention. AI-Mind will develop two artificial intelligence-based digital tools that will identify dysfunctional brain networks and assess dementia risk. Personalised patient reports will be generated, potentially opening new windows for intervention possibilities.
Objective
More than 10 million Europeans show signs of mild cognitive impairment (MCI), a condition intermediate between normal brain ageing and dementia. The evolution of MCI differs from person to person; some remain stable or return to normal, but 50% progress to dementia within five years. Current practice lacks the necessary screening tools to identify those 50% at risk. The patient’s journey typically takes many years of inefficient clinical follow-ups before a conclusive diagnosis is finally reached.
AI-Mind will radically shorten this journey to 1 week through a digital solution that is able to provide a fast and accurate (>95%) prediction for the individual dementia risk. Our AI-Mind platform service, can be easily integrated into existing clinical practices and contains 2 new artificial-intelligence-based tools. The AI-Mind Connector identifies dysfunctional brain networks. The AI-Mind Predictor assesses demen-tia risk using data from the Connector, advanced cognitive tests, genetic biomarkers and important textual variables. Our aim is to set up a European clinical network that will upload patient data to the AI-Mind European cloud platform.
The consortium comprises excellent researchers in neuroscience and computer science, from 5 clinical cen-tres, who closely collaborate with 3 SMEs contributing unique technologies, an established data govern-ance body, and Alzheimer Europe. Together, they plan to deliver a medical device of class 2b that can reach TRL7 by the end of the project. AI-Mind represents a major step forward in the risk assessment of dementia. Clinicians will promptly advise therapies to delay the onset of disease, and patients will enjoy independent lives for longer. By offering a globally accessible, cheap and precise tool for dementia pre-diction, AI-Mind will improve the health care system and boost innovation by shifting the R&D of phar-maceutical organisations and other companies to preventive diagnostic methods and therapies for dementia.
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
0450 Oslo
Norway
See on map
Participants (20)
02150 Espoo
See on map
8008 ZURICH
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1736 SENNINGERBERG
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
0784 OLSO
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1363 Hovik
See on map
00029 Helsinki
See on map
00163 Roma Rm
See on map
28938 MOSTOLES
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
00168 Roma
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
0167 Oslo
See on map
Participation ended
6525 XZ Nijmegen
See on map
10120 Tallinn
See on map
28040 Madrid
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
28040 Madrid
See on map
20123 Milano
See on map
6525 GA Nijmegen
See on map
0313 Oslo
See on map
0382 Oslo
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
4070 Basel
See on map
6343 Rotkreuz
See on map